VanEck Biotech ETF (BBH) Volatility Skew
Implied volatility skew shows how IV varies across strike prices for a given expiration. Steeper skews indicate higher demand for downside protection relative to upside speculation.
VanEck Biotech ETF (BBH) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $369.1M, listed on NASDAQ, carrying a beta of 0.60 to the broader market. VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. public since 1999-11-23.
Snapshot as of May 15, 2026.
- Spot Price
- $182.24
- ATM IV
- 21.9%
- IV Skew 25Δ
- -0.002
- IV Rank
- 28.2%
- IV Percentile
- 55.6%
- Term Structure Slope
- 0.003
As of May 15, 2026, VanEck Biotech ETF (BBH) at-the-money implied volatility is 21.9%. IV rank is 28.2% (where 0% is the 52-week low and 100% is the 52-week high). IV percentile is 55.6%. The 25-delta skew is -0.002: skew is roughly flat across the 25-delta wings. High IV rank typically favors premium-selling strategies; low IV rank favors premium-buying.
BBH Strategy Selection at Current Volatility Levels
For VanEck Biotech ETF options at 21.9% ATM IV, low IV rank (28.2%) favors premium-buying or long-vol structures: long calls or puts, debit spreads, calendar spreads, long straddles. The risk: low-rank regimes can persist for months while time decay eats premium-buyers alive. Pair the vol-rank read with the dealer-gamma view and the upcoming-events calendar to confirm the strategy fits both the structural regime and the path-dependent risk. The variance risk premium - the persistent gap between implied and subsequently realized vol - is positive in equity markets on average; high IV rank typically reflects a stretch where the premium is wider than usual.
Learn how volatility skew is reported and how to read the data →
Frequently asked BBH volatility skew questions
- What is the current BBH ATM implied volatility?
- As of May 15, 2026, VanEck Biotech ETF (BBH) at-the-money implied volatility is 21.9%. IV rank is 28.2% on a 0-100% scale anchored to the 1-year IV range. ATM IV is the volatility input that makes a Black-Scholes-equivalent model reproduce the listed at-the-money option prices.
- Is BBH IV high or low historically?
- IV is subdued relative to its 1-year history, conditions that typically favor premium-buying strategies (long calls, long puts, debit spreads, calendar spreads).
- What does BBH volatility skew tell options traders?
- Volatility skew is the pattern by which IV varies across strikes for a given expiration. VanEck Biotech ETF skew is roughly flat across the 25-delta wings. Skew matters for risk-defined strategy selection: when downside puts are rich, put-credit spreads capture more premium; when upside calls are rich, call-credit spreads or covered-call writes harvest more.